Do analysts rate FOXX or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foxx Development 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer FOXX or QCLS?

In the previous week, Foxx Development had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 3 mentions for Foxx Development and 2 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 0.00 beat Foxx Development's score of -0.04 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foxx Development 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer EBON or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ebang International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, EBON or QCLS?

Mymd Pharmaceuticals has lower revenue, but higher earnings than Ebang International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ebang International $6.54M 2.01 -$14.09M N/A N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$3.48 N/A

Is EBON or QCLS more profitable?

Ebang International's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Ebang International N/A N/A N/A Mymd Pharmaceuticals N/A -91.64% -47.48%

Does the media favor EBON or QCLS?

In the previous week, Mymd Pharmaceuticals had 1 more articles in the media than Ebang International. MarketBeat recorded 2 mentions for Mymd Pharmaceuticals and 1 mentions for Ebang International. Ebang International's average media sentiment score of 1.22 beat Mymd Pharmaceuticals' score of 0.00 indicating that Ebang International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ebang International 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AIMD or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AIMD or QCLS more profitable?

Mymd Pharmaceuticals' return on equity of -91.64% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Ainos N/A -217.50% -67.87% Mymd Pharmaceuticals N/A -91.64% -47.48%

Does the media prefer AIMD or QCLS?

In the previous week, Ainos and Ainos both had 2 articles in the media. Ainos' average media sentiment score of 0.14 beat Mymd Pharmaceuticals' score of 0.00 indicating that Ainos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ainos 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BOXL or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boxlight 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor BOXL or QCLS?

In the previous week, Mymd Pharmaceuticals had 1 more articles in the media than Boxlight. MarketBeat recorded 2 mentions for Mymd Pharmaceuticals and 1 mentions for Boxlight. Boxlight's average media sentiment score of 1.07 beat Mymd Pharmaceuticals' score of 0.00 indicating that Boxlight is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boxlight 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate QCLS or AGMH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, QCLS or AGMH?

AGM Group has higher revenue and earnings than Mymd Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mymd Pharmaceuticals N/A N/A -$11.63M -$3.48 N/A AGM Group $30.56M 0.08 $560K N/A N/A

Is QCLS or AGMH more profitable?

AGM Group's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -91.64% -47.48% AGM Group N/A N/A N/A

Does the media favor QCLS or AGMH?

In the previous week, AGM Group had 11 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 13 mentions for AGM Group and 2 mentions for Mymd Pharmaceuticals. AGM Group's average media sentiment score of 0.92 beat Mymd Pharmaceuticals' score of 0.00 indicating that AGM Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AGM Group 5 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mymd Pharmaceuticals (QCLS) Competitors

$0.68 -0.07 (-9.02%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$0.67 -0.01 (-1.25%)

As of 10/5/2026 07:56 PM Eastern

Compare

QCLS vs. FOXX, EBON, AIMD, BOXL, and AGMH

Should you buy Mymd Pharmaceuticals stock or one of its competitors? Mymd Pharmaceuticals's main competitors and comparable companies include Foxx Development (FOXX), Ebang International (EBON), Ainos (AIMD), Boxlight (BOXL), and AGM Group (AGMH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "technology hardware, storage & peripherals" industry.

How does Mymd Pharmaceuticals compare to Foxx Development?

Foxx Development (NASDAQ:FOXX) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Foxx Development has a beta of -0.34, meaning that its stock price is 134% less volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foxx Development	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Foxx Development had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 3 mentions for Foxx Development and 2 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 0.00 beat Foxx Development's score of -0.04 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foxx Development	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mymd Pharmaceuticals has lower revenue, but higher earnings than Foxx Development. Foxx Development is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foxx Development	$52.58M	0.34	-$52.69M	-$7.53	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A

60.4% of Foxx Development shares are owned by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 31.6% of Foxx Development shares are owned by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mymd Pharmaceuticals has a net margin of 0.00% compared to Foxx Development's net margin of -100.20%. Foxx Development's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foxx Development	-100.20%	N/A	-74.38%
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%

Summary

Mymd Pharmaceuticals beats Foxx Development on 7 of the 12 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Ebang International?

Ebang International (NASDAQ:EBON) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap technology companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ebang International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ebang International has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market.

In the previous week, Mymd Pharmaceuticals had 1 more articles in the media than Ebang International. MarketBeat recorded 2 mentions for Mymd Pharmaceuticals and 1 mentions for Ebang International. Ebang International's average media sentiment score of 1.22 beat Mymd Pharmaceuticals' score of 0.00 indicating that Ebang International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ebang International	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.2% of Ebang International shares are owned by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 25.4% of Ebang International shares are owned by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ebang International's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ebang International	N/A	N/A	N/A
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%

Mymd Pharmaceuticals has lower revenue, but higher earnings than Ebang International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ebang International	$6.54M	2.01	-$14.09M	N/A	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A

Summary

Ebang International beats Mymd Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Ainos?

Ainos (NASDAQ:AIMD) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 9.8% of Ainos shares are owned by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Ainos and Ainos both had 2 articles in the media. Ainos' average media sentiment score of 0.14 beat Mymd Pharmaceuticals' score of 0.00 indicating that Ainos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ainos	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mymd Pharmaceuticals has lower revenue, but higher earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$13.60K	722.11	-$14.77M	-$2.52	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A

Ainos has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mymd Pharmaceuticals' return on equity of -91.64% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	N/A	-217.50%	-67.87%
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%

Summary

Ainos and Mymd Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Boxlight?

Boxlight (NASDAQ:BOXL) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap technology companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Mymd Pharmaceuticals has lower revenue, but higher earnings than Boxlight. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Boxlight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boxlight	$104.33M	0.04	-$23.81M	-$80.86	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boxlight	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Boxlight has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market.

Mymd Pharmaceuticals has a net margin of 0.00% compared to Boxlight's net margin of -20.96%. Boxlight's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boxlight	-20.96%	N/A	-23.50%
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%

6.5% of Boxlight shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 15.4% of Boxlight shares are held by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Mymd Pharmaceuticals had 1 more articles in the media than Boxlight. MarketBeat recorded 2 mentions for Mymd Pharmaceuticals and 1 mentions for Boxlight. Boxlight's average media sentiment score of 1.07 beat Mymd Pharmaceuticals' score of 0.00 indicating that Boxlight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boxlight	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Boxlight and Mymd Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to AGM Group?

Mymd Pharmaceuticals (NASDAQ:QCLS) and AGM Group (NASDAQ:AGMH) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Mymd Pharmaceuticals has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market. Comparatively, AGM Group has a beta of 2.58, indicating that its share price is 158% more volatile than the broader market.

AGM Group has higher revenue and earnings than Mymd Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$3.48	N/A
AGM Group	$30.56M	0.08	$560K	N/A	N/A

AGM Group's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-91.64%	-47.48%
AGM Group	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by insiders. Comparatively, 34.9% of AGM Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, AGM Group had 11 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 13 mentions for AGM Group and 2 mentions for Mymd Pharmaceuticals. AGM Group's average media sentiment score of 0.92 beat Mymd Pharmaceuticals' score of 0.00 indicating that AGM Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AGM Group	5 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AGM Group beats Mymd Pharmaceuticals on 8 of the 9 factors compared between the two stocks.

Get Mymd Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QCLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QCLS vs. The Competition

Export

Metric	Mymd Pharmaceuticals	Technology Hardware, Storage & Peripherals Industry	Technology Sector	NASDAQ Exchange
Market Cap	$6.13M	$120.64B	$31.93B	$13.26B
Dividend Yield	N/A	1.65%	2.75%	17.36%
P/E Ratio	-0.20	31.89	82.01	26.20
Price / Sales	N/A	43.93	586.02	95.18
Price / Cash	N/A	22.94	48.60	34.70
Price / Book	0.13	8.50	8.22	6.40
Net Income	-$11.63M	$3.49B	$766.00M	$381.07M
7 Day Performance	-23.82%	-0.96%	1.53%	-0.28%
1 Month Performance	-61.98%	-3.46%	0.35%	-4.51%
1 Year Performance	N/A	52.34%	167.51%	1.63%

Mymd Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QCLS Mymd Pharmaceuticals	0.2292 of 5 stars	$0.68 -9.0%	N/A	N/A	$6.13M	N/A	N/A	2	Gap Down
FOXX Foxx Development	0.7375 of 5 stars	$2.50 +1.0%	N/A	-43.6%	$18.52M	$65.92M	N/A	25
EBON Ebang International	1.225 of 5 stars	$2.03 +1.0%	N/A	-61.9%	$14.14M	$6.54M	N/A	197	Positive News
AIMD Ainos	0.3174 of 5 stars	$1.44 +3.2%	N/A	-62.3%	$10.41M	$120K	N/A	41	Gap Down High Trading Volume
BOXL Boxlight	0.6418 of 5 stars	$4.79 -2.8%	N/A	-94.5%	$3.22M	$109.25M	N/A	155	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QCLS) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. FOXX, EBON, AIMD, BOXL, and AGMH

How does Mymd Pharmaceuticals compare to Foxx Development?

Summary

How does Mymd Pharmaceuticals compare to Ebang International?

Summary

How does Mymd Pharmaceuticals compare to Ainos?

Summary

How does Mymd Pharmaceuticals compare to Boxlight?

Summary

How does Mymd Pharmaceuticals compare to AGM Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. FOXX, EBON, AIMD, BOXL, and AGMH

How does Mymd Pharmaceuticals compare to Foxx Development?

Which has more risk & volatility, FOXX or QCLS?

Do analysts rate FOXX or QCLS?

Does the media prefer FOXX or QCLS?

Which has stronger valuation & earnings, FOXX or QCLS?

Do insiders & institutionals have more ownership in FOXX or QCLS?

Is FOXX or QCLS more profitable?

Summary

How does Mymd Pharmaceuticals compare to Ebang International?

Do analysts prefer EBON or QCLS?

Which has more volatility and risk, EBON or QCLS?

Does the media favor EBON or QCLS?

Do insiders and institutionals believe in EBON or QCLS?

Is EBON or QCLS more profitable?

Which has preferable valuation and earnings, EBON or QCLS?

Summary

How does Mymd Pharmaceuticals compare to Ainos?

Do insiders & institutionals believe in AIMD or QCLS?

Does the media prefer AIMD or QCLS?

Which has preferable valuation & earnings, AIMD or QCLS?

Which has more volatility and risk, AIMD or QCLS?

Do analysts rate AIMD or QCLS?

Is AIMD or QCLS more profitable?

Summary

How does Mymd Pharmaceuticals compare to Boxlight?

Which has better valuation & earnings, BOXL or QCLS?

Do analysts rate BOXL or QCLS?

Which has more volatility & risk, BOXL or QCLS?

Is BOXL or QCLS more profitable?

Do insiders and institutionals have more ownership in BOXL or QCLS?

Does the media favor BOXL or QCLS?

Summary

How does Mymd Pharmaceuticals compare to AGM Group?

Which has more risk & volatility, QCLS or AGMH?

Which has stronger valuation & earnings, QCLS or AGMH?

Is QCLS or AGMH more profitable?

Do analysts rate QCLS or AGMH?

Do insiders & institutionals believe in QCLS or AGMH?

Does the media favor QCLS or AGMH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools